A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

Summary

This is a Phase 1a/1b, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of TER-1754 (a novel AKT1 inhibitor) in patients with HHT.

Timeline

Start

2025-12-15

Primary completion

2028-03

Completion

2028-03

Outcome

Outcome not reported

Stopped (Enrollment): “This decision is based solely on internal company prioritization and resource allocation considerations. No patients have been enrolled or dosed in this study and no clinical data have been generated.”

Drugs

Indications